BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
BC Week In Review | Jul 27, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BC Extra | Jul 26, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BioCentury | Apr 28, 2017
Emerging Company Profile

Cutting cravings

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...
BC Week In Review | Feb 17, 2017
Company News

Gilead, Amygdala deal

Amygdala acquired GS-6637 from Gilead. Gilead received an equity stake and is eligible for undisclosed milestones and royalties. Amygdala expects to begin two or three Phase II trials this year of GS-6637 in alcohol and...
BC Extra | Feb 16, 2017
Company News

Amygdala acquires addiction candidate from Gilead

Amygdala Neurosciences Inc. (Palo Alto, Calif.) said it acquired GS-6637 from Gilead Sciences Inc. (NASDAQ:GILD). The company expects to begin clinical trials this year of the candidate to treat cocaine and alcohol use disorders. GS-6637...
BC Week In Review | Jul 14, 2014
Clinical News

Ranolazine: Phase II data

The double-blind, international Phase II HARMONY trial in 134 patients with paroxysmal AF showed that twice-daily 750 mg oral ranolazine plus 150 and 225 mg dronedarone each led to greater reductions in AF burden from...
BioCentury | Aug 5, 2013
Regulation

Rushing to abandon tQT

FDA 's Norman Stockbridge wants to abandon thorough QT studies by 2015, replacing them with a preclinical assay suite better able to detect proarrhythmia side effects than existing assays. However, it remains unclear whether two...
BC Week In Review | Apr 15, 2013
Company News

Terrapin management update

Terrapin Technologies Inc., South San Francisco, Calif.   Business: Drug discovery   Hired: Michael Wick as EVP of R&D and COO, formerly SVP of research at CV Therapeutics Inc.  ...
BC Week In Review | Aug 20, 2012
Clinical News

CPAPP-A* test: Pivotal trial data

Beckman Coulter Inc. reported data from an analysis of 3,782 patients with non-ST-segment-elevation myocardial infarction (NSTEMI) ACS in the double-blind, placebo-controlled, international Phase III MERLIN-TIMI 36 trial of Ranexa ranolazine to treat ACS showing that...
Items per page:
1 - 10 of 554
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
BC Week In Review | Jul 27, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BC Extra | Jul 26, 2018
Company News

Milligan, Martin leaving Gilead

Gilead Sciences Inc. (NASDAQ:GILD) said President and CEO John Milligan will step down at year end. The company's board is searching for a successor. Milligan has been at Gilead for 28 years. He became CEO...
BioCentury | Apr 28, 2017
Emerging Company Profile

Cutting cravings

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...
BC Week In Review | Feb 17, 2017
Company News

Gilead, Amygdala deal

Amygdala acquired GS-6637 from Gilead. Gilead received an equity stake and is eligible for undisclosed milestones and royalties. Amygdala expects to begin two or three Phase II trials this year of GS-6637 in alcohol and...
BC Extra | Feb 16, 2017
Company News

Amygdala acquires addiction candidate from Gilead

Amygdala Neurosciences Inc. (Palo Alto, Calif.) said it acquired GS-6637 from Gilead Sciences Inc. (NASDAQ:GILD). The company expects to begin clinical trials this year of the candidate to treat cocaine and alcohol use disorders. GS-6637...
BC Week In Review | Jul 14, 2014
Clinical News

Ranolazine: Phase II data

The double-blind, international Phase II HARMONY trial in 134 patients with paroxysmal AF showed that twice-daily 750 mg oral ranolazine plus 150 and 225 mg dronedarone each led to greater reductions in AF burden from...
BioCentury | Aug 5, 2013
Regulation

Rushing to abandon tQT

FDA 's Norman Stockbridge wants to abandon thorough QT studies by 2015, replacing them with a preclinical assay suite better able to detect proarrhythmia side effects than existing assays. However, it remains unclear whether two...
BC Week In Review | Apr 15, 2013
Company News

Terrapin management update

Terrapin Technologies Inc., South San Francisco, Calif.   Business: Drug discovery   Hired: Michael Wick as EVP of R&D and COO, formerly SVP of research at CV Therapeutics Inc.  ...
BC Week In Review | Aug 20, 2012
Clinical News

CPAPP-A* test: Pivotal trial data

Beckman Coulter Inc. reported data from an analysis of 3,782 patients with non-ST-segment-elevation myocardial infarction (NSTEMI) ACS in the double-blind, placebo-controlled, international Phase III MERLIN-TIMI 36 trial of Ranexa ranolazine to treat ACS showing that...
Items per page:
1 - 10 of 554